Clinical Trials Logo

Filter by:
NCT ID: NCT05173922 Active, not recruiting - Alzheimer Disease Clinical Trials

"Safety in Dementia": An Online Caregiver Intervention

Start date: May 22, 2022
Phase: N/A
Study type: Interventional

In an online randomized trial of Safety in Dementia with national recruitment and longitudinal follow-up, we will recruit informal caregivers of community-dwelling adults with dementia who have firearm access.

NCT ID: NCT05173818 Active, not recruiting - Clinical trials for Concussion Post Syndrome

Hyperbaric Oxygen Effects on Persistent Post-concussive Symptoms

HOINPCS
Start date: June 28, 2022
Phase: Phase 2
Study type: Interventional

Persistent post-concussive symptoms (PPCS) are a source of significant burden among a subset of patients with concussion with prevalence rates previously reported between 11 - 82% based on timing of assessment, diagnostic criteria, or population under study. Examples of persistent post-concussion symptoms include balance problems, headaches, fatigue, poor concentration, forgetfulness, anxiety, irritability, and sleep disturbance. Few proposed therapies have proved successful in the management of persistent post-concussion symptoms following mild traumatic brain injury. The investigators will explore hyperbaric oxygen administered in a randomized sham-controlled clinical trial as an effective and tolerable treatment in improving neuropsychological status among adult patients with persistent post-concussive symptoms. The overall hypothesis to be evaluated is that hyperbaric oxygen improves neuropsychological status and a serum concussion biomarker associated with PPCS.

NCT ID: NCT05173532 Active, not recruiting - Clinical trials for Pulmonary Disease, Chronic Obstructive

The Prescriptive Validity of a Novel Fall Risk Clinical Prediction Rule for People With COPD

Start date: February 10, 2021
Phase: N/A
Study type: Interventional

This study has 3 objectives: (1) demonstrate the effectiveness of balance training for people with COPD, (2) determine which patients with COPD respond best to balance training, and (3) calculate clinically meaningful changes in balance for patients with COPD.

NCT ID: NCT05172596 Active, not recruiting - Multiple Myeloma Clinical Trials

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

Start date: March 7, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple myeloma

NCT ID: NCT05171881 Active, not recruiting - Cerebral Hypoxia Clinical Trials

Brain Oxygenation-II

BOx-II
Start date: April 7, 2022
Phase: Phase 2
Study type: Interventional

The Brain Oxygenation-II study (BOx-II) is a phase-II, multicenter, single-arm clinical trial evaluating interventions based on near-infrared spectroscopy (NIRS) monitoring of cerebral oxygen saturation in extremely premature infants. Enrolled infants will follow a treatment guideline to maintain cerebral oxygen saturation in a target range within the first 72 hours of life. The primary outcomes will include interventions used to maintain cerebral saturation in target range, rates of cerebral hypoxia and systemic hypoxia, and a composite of death or severe brain injury detected on term-equivalent magnetic resonance imaging.

NCT ID: NCT05171855 Active, not recruiting - Clinical trials for Endocrine System Diseases

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Start date: December 16, 2021
Phase: Phase 3
Study type: Interventional

This is a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly. The study participants are adults (males and females) with confirmed growth hormone deficiency (GHD) having completed the treatment period in study TCH-306 (foresiGHt).

NCT ID: NCT05171777 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Start date: April 4, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC. Two populations will be included: participants with resected Stage II, IIIA, and selected IIIB (T3-N2) NSCLC who have completed adjuvant platinum-based chemotherapy without evidence of disease relapse/recurrence, and chemotherapy-naïve participants with Stage IV NSCLC. The study will evaluate participant- and healthcare professionals (HCP)-reported preference for atezolizumab subcutaneous (SC) compared with atezolizumab intravenous (IV).

NCT ID: NCT05171491 Active, not recruiting - Clinical trials for Solitary Pulmonary Nodule

LungLB in Subjects Presenting With Indeterminate Pulmonary Nodules

Start date: January 26, 2022
Phase:
Study type: Observational

Correlate performance of LungLB Test with outcome of a scheduled biopsy.

NCT ID: NCT05171257 Active, not recruiting - Clinical trials for Gram-Negative Bacterial Infections

Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit

RESTART
Start date: October 19, 2021
Phase:
Study type: Observational

Antimicrobial resistance is a global health emergency estimated to be responsible for 700,000 deaths per year worldwide, and it is well known that previous antibiotic exposure is the single most contributing factor. For example, the use of non-antipseudomonal agents can increase risk for any P. aeruginosa strain; however, the use of an agent with antipseudomonal activity would select for resistance to that particular antimicrobial agent or class. Demonstrated that each additional day of exposure to any antipseudomonal beta-lactam is associated with an increased risk of new resistance development. The study seeks to determine whether the choice of empiric therapy (i.e., the same agent versus a different agent from prior antibiotic exposure) has any effect on the likelihood of in vitro activity against GN pathogens (GNPs) in a subsequent infection.

NCT ID: NCT05170425 Active, not recruiting - Clinical trials for Lung Transplant Rejection

LAMBDA 002 (Lung Registry) Study

Start date: November 4, 2022
Phase:
Study type: Observational [Patient Registry]

The LAMBDA 002 registry study is an observational, longitudinal, multi-center study observing patients undergoing lung transplant.